Dyslipidemia is a disruption in the amount of lipids in the blood.
Building on their recent research focusing on a peptide, pNaKtide, designed to block the oxidant amplifying function of the cellular sodium-potassium pump, researchers at Marshall University Joan C. Edwards School of Medicine have successfully demonstrated that pNaKtide, can attenuate the development of experimental nonalcoholic fatty liver disease (NAFLD) and atherosclerosis.
A two year follow-up on a study involving more than 10,000 people with stable chest pain finds that an online tool can accurately predict which patients are likely to have normal non-invasive tests and remain free of cardiac events.
A new study of U.S. adolescents shows an association between metabolic syndrome and impairments in reading, attention, and working memory.
The U.S. Preventive Services Task Force has issued a recommendation statement regarding the use of statins for primary prevention of cardiovascular disease in adults. The report appears in the November 15 issue of JAMA.
The incidence of coronary heart disease in the U.S. declined nearly 20 percent from 1983 to 2011, according to a study appearing in the November 15 issue of JAMA.
Allergan plc, a leading global pharmaceutical company, today announced the availability of TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1mg/20mcg, the first and only oral contraceptive in a softgel capsule for the prevention of pregnancy
To the tantalizing delight of chocolate lovers everywhere, a number of recent studies employing various methods have suggested that compounds in cocoa called flavanols could benefit cardiovascular health.
Survival and other cardiovascular outcomes were not significantly reduced with intensive treatment using a second-line cholesterol-lowering medication on top of a standard statin, compared to statin treatment alone in patients with acute coronary syndrome (ACS) and dyslipidemia, investigators reported here.
Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, can significantly reduce or even eliminate their need for expensive and time-consuming apheresis treatments with the PCSK9 inhibitor alirocumab.
A new study shows a brisk walk is just as good as a jog when it comes to reducing liver fatty content, important news for the more than 3 million people diagnosed each year in the U.S. with nonalcoholic fatty liver disease (NAFLD).
Researchers at University of California San Diego School of Medicine and University of California, San Francisco School of Medicine report that more than 1 in 3 atrial fibrillation (AF) patients at intermediate to high risk for stroke are treated with aspirin alone, despite previous data showing this therapy to be inferior to blood thinners.
Significant improvements seen across multiple sociodemographic groups, according to a new study in the American Journal of Preventive Medicine
Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.
Adding to the already length list of reasons not to smoke, researchers have connected smoking to worsening degenerative disc disease in the cervical spine, according to research presented this week at the Association of Academic Physiatrists Annual Meeting in Sacramento, Calif.
Researchers have new insight into the complex interchange that can raise blood levels of unhealthy lipids, or fat, in type 1 diabetes, and early evidence that a drug under study to block cancer cell growth can restore healthier levels.
Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan.
A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.
Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.
The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco.
Obesity is a leading cause of complications and death in children suffering from Prader-Willi syndrome (PWS), yet there are few effective treatment options for these patients. In a new study published in Surgery for Obesity and Related Disease researchers found that bariatric surgery, specifically laparoscopic sleeve gastrectomy (LSG), resulted in substantial weight loss with no apparent adverse effect on growth in a small group of severely overweight patients with PWS.